Updated

Amgen announced October 24 that a drug combination reduced the risk of death by 58% in patients with aggressive lung cancer when added to an immunotherapy from AstraZeneca. The combination offers patients with this severe form of cancer significantly extended survival time, representing a meaningful clinical advance in oncology treatment.